Global Influenza Diagnostics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• February 2021, Becton, Dickinson and Company (US) received emergency use authorization (EUA) from the FDA for a new molecular diagnostic test that detects both SARS-CoV-2 and influenza A+B.
• March 2021, Abbott Laboratories, Inc. (US) received emergency use authorization (EUA) from the FDA for a laboratory PCR assay that detects and differentiates SARS-CoV-2, flu A, flu B, and RSV in a single test.
• May 2021, Becton, Dickinson and Company (US) received FDA approval for the BD Veritor Plus System, which detects SARS-CoV-2, influenza A, and influenza B.

The global influenza diagnostics market is witnessing significant growth, primarily driven by the increasing prevalence of influenza infections worldwide. As influenza outbreaks continue to pose a considerable public health challenge, the demand for effective diagnostic tools is on the rise. Technological advancements in diagnostic techniques, such as rapid molecular testing and point-of-care testing, are further fueling market expansion. These innovative approaches offer quicker and more accurate detection of influenza viruses, enabling healthcare providers to initiate timely treatment and implement appropriate infection control measures.

Molecular techniques, includes PCR, INAAT-NASBAT, and TMABAS, each offering unique advantages in the detection and diagnosis of influenza. PCR (Polymerase Chain Reaction) is one of the most widely used molecular methods for diagnosing influenza, known for its high sensitivity and specificity. PCR can detect the genetic material of the influenza virus, enabling early and accurate diagnosis, even during low viral loads. This makes it particularly useful in clinical settings where rapid and precise identification is crucial for effective patient management.

Pandemic has underscored the importance of robust influenza diagnostics, as symptoms of influenza and COVID-19 can overlap, leading to diagnostic challenges. Consequently, there has been a heightened emphasis on developing multiplex diagnostic assays capable of simultaneously detecting influenza viruses and SARS-CoV-2, the virus responsible for COVID-19. This convergence of efforts to combat both influenza and COVID-19 is expected to drive the adoption of advanced diagnostic solutions in healthcare settings globally.

Geographically, North America dominates the global influenza diagnostics market, owing to the presence of a well-established healthcare infrastructure, high healthcare expenditure, and proactive government initiatives to control infectious diseases. However, the Asia-Pacific region is poised to witness significant growth in the coming years, fueled by increasing awareness about influenza prevention, rising healthcare expenditure, and expanding access to advanced diagnostic technologies. Furthermore, growing investments by key market players in emerging economies of Asia-Pacific are anticipated to drive market growth in the region.

The global influenza diagnostics market is experiencing robust growth driven by technological advancements, the convergence of influenza and COVID-19 diagnostic efforts, and increasing healthcare investments in emerging markets. With a growing emphasis on early detection and prompt treatment of influenza infections, the market is expected to witness continued expansion in the foreseeable future.

Global Influenza Diagnostics Segment Analysis

In this report, the Global Influenza Diagnostics Market has been segmented by Test Type, Molecular, End Users and Geography.

Global Influenza Diagnostics Market, Segmentation by Test Type

The Global Influenza Diagnostics Market has been segmented by Test Type into Traditional Diagnostic Test and Molecular Diagnostic Assay.

The Global Influenza Diagnostics Market is witnessing significant growth, largely driven by the increasing prevalence of influenza worldwide. One of the primary factors contributing to this growth is the adoption of advanced diagnostic techniques. The market has been segmented into two main test types: Traditional Diagnostic Test and Molecular Diagnostic Assay.

Traditional diagnostic tests typically involve methods like rapid influenza diagnostic tests (RIDTs) and viral culture assays. These tests are known for their quick turnaround time and ease of use, making them particularly valuable in settings where immediate results are necessary, such as emergency departments and clinics.

Molecular diagnostic assays, which include techniques like polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), offer higher sensitivity and specificity compared to traditional tests. They enable the detection of influenza viruses with greater accuracy, making them essential in surveillance programs and outbreak investigations.

The demand for influenza diagnostics is further fueled by the growing awareness about the importance of early detection and treatment of influenza infections, especially during seasonal outbreaks and pandemics. Additionally, advancements in technology, such as the development of point-of-care testing devices, are expected to drive market growth by enhancing accessibility and convenience for patients and healthcare providers.

Global Influenza Diagnostics Market, Segmentation by Molecular

The Global Influenza Diagnostics Market has been segmented by Molecular into PCR, INAAT- NASBAT, TMABAS

The global influenza diagnostics market, segmented by molecular techniques, includes PCR, INAAT-NASBAT, and TMABAS, each offering unique advantages in the detection and diagnosis of influenza. PCR (Polymerase Chain Reaction) is one of the most widely used molecular methods for diagnosing influenza, known for its high sensitivity and specificity. PCR can detect the genetic material of the influenza virus, enabling early and accurate diagnosis, even during low viral loads. This makes it particularly useful in clinical settings where rapid and precise identification is crucial for effective patient management.

INAAT-NASBAT (In-Nasal Amplification Test for Nucleic Acid-based Shortened Amplification Test) represents a newer and more innovative molecular diagnostic technique. It is designed to provide quicker results by directly detecting viral nucleic acids from nasal samples. This method is gaining popularity due to its potential for near-patient testing, offering faster turnaround times compared to traditional PCR. The ease of use and rapid results are especially beneficial in point-of-care settings, making it a promising tool for influenza detection, particularly in emergency departments and clinics.

TMABAS (Tandem Mass Spectrometry for Antibody-Based Antigen Subtyping) is another molecular diagnostic approach used in the influenza diagnostics market. While it is less commonly employed than PCR or INAAT-NASBAT, it offers the advantage of identifying specific subtypes of the influenza virus, which is critical for epidemiological surveillance and vaccine development. TMABAS enables more detailed analysis of influenza strains, providing valuable information on the circulating virus and helping to guide treatment and prevention strategies. As the need for more precise subtyping grows, the application of TMABAS may expand, further contributing to the molecular diagnostics landscape.

Global Influenza Diagnostics Market, Segmentation by End Users

The Global Influenza Diagnostics Market has been segmented by End Users into Hospital, Research Laboratory and Other End Users.

The global influenza diagnostics market has witnessed significant growth in recent years, driven by factors such as the increasing prevalence of influenza outbreaks worldwide and the growing awareness regarding early diagnosis and management of the disease. One of the key aspects influencing this market is the segmentation by end users, which helps in tailoring diagnostic solutions to specific needs.

The hospital segment holds a dominant position in the market, accounting for a substantial share. Hospitals are often the primary points of contact for individuals seeking medical assistance, and they play a crucial role in the diagnosis, treatment, and management of influenza cases. As a result, the demand for influenza diagnostic tests and equipment is high within hospital settings.

Research laboratories also represent a significant end-user segment in the global influenza diagnostics market. These laboratories are involved in conducting advanced research studies aimed at understanding the epidemiology, transmission dynamics, and genetic characteristics of influenza viruses. They require sophisticated diagnostic tools and technologies to carry out their research effectively, thereby contributing to the demand for influenza diagnostics.

Apart from hospitals and research laboratories, other end users, such as clinics, diagnostic centers, and public health institutions, also contribute to the market growth. These end users cater to diverse patient populations and are essential in ensuring timely diagnosis and surveillance of influenza outbreaks. The availability of rapid diagnostic tests and point-of-care devices has further facilitated the adoption of influenza diagnostics across various healthcare settings.

The segmentation by end users plays a pivotal role in driving the growth of the global influenza diagnostics market. By understanding the specific requirements and preferences of different end-user segments, manufacturers and suppliers can develop targeted solutions that meet the evolving needs of healthcare providers and researchers involved in combating influenza.

Global Influenza Diagnostics Market, Segmentation by Geography

In this report, the Global Influenza Diagnostics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Influenza Diagnostics Market Share (%), by Geographical Region, 2024

The global influenza diagnostics market is witnessing significant growth, driven by several factors such as the increasing prevalence of influenza infections worldwide, rising awareness about early diagnosis and treatment, and the development of advanced diagnostic technologies. In this report, the market has been segmented by geography into five key regions: North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

North America holds a substantial share in the global influenza diagnostics market, primarily due to the presence of advanced healthcare infrastructure, high healthcare expenditure, and proactive government initiatives to control influenza outbreaks. Additionally, the region benefits from the presence of major market players and ongoing research and development activities aimed at enhancing diagnostic accuracy and efficiency.

Europe follows closely behind, driven by the rising incidence of influenza infections and the increasing adoption of rapid diagnostic tests (RDTs) for influenza detection. Countries like the UK, Germany, and France are at the forefront of market growth, supported by robust healthcare systems and favorable reimbursement policies.

The Asia Pacific region is expected to witness rapid growth in the influenza diagnostics market, fueled by the growing healthcare expenditure, increasing awareness about infectious diseases, and expanding access to healthcare services in emerging economies like China, India, and Japan. Moreover, the rising prevalence of influenza strains in the region is further propelling market expansion.

In the Middle East and Africa region, the market is poised to experience steady growth, supported by improving healthcare infrastructure, rising healthcare investments, and government initiatives to combat infectious diseases. However, challenges such as limited access to healthcare facilities and resources may hinder market growth to some extent.

Latin America also presents significant growth opportunities for the influenza diagnostics market, driven by the increasing incidence of influenza infections, expanding healthcare infrastructure, and growing awareness about the importance of early diagnosis and prompt treatment. Market players are increasingly focusing on expanding their presence in this region through strategic collaborations and partnerships with local healthcare providers and distributors.

This report provides an in depth analysis of various factors that impact the dynamics of Global Influenza Diagnostics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers

• Technological advancements spur growth
• Rising prevalence demands diagnostics
• Increasing healthcare expenditure supports
• Growing awareness boosts demand

• Pandemic preparedness drives innovation: The global influenza diagnostics market has experienced significant growth, driven largely by the pressing need for pandemic preparedness. With outbreaks like the H1N1 influenza pandemic of 2009 and the more recent COVID-19 pandemic, there has been a heightened awareness of the importance of early detection and rapid response to infectious diseases. This awareness has fueled innovation in influenza diagnostics, leading to the development of advanced testing methods such as nucleic acid amplification tests (NAATs), rapid influenza diagnostic tests (RIDTs), and next-generation sequencing (NGS) technologies. These innovations not only enable healthcare providers to accurately diagnose influenza infections but also facilitate surveillance efforts to monitor the spread of the virus and inform public health interventions.

  The increasing adoption of point-of-care testing (POCT) solutions has contributed to the growth of the influenza diagnostics market. POCT devices offer the advantage of delivering rapid results, allowing for timely clinical decision-making and patient management. Moreover, advancements in technology have led to the development of more accurate and sensitive diagnostic assays, enhancing the reliability of influenza testing. As governments and healthcare organizations worldwide recognize the importance of preparedness for potential influenza pandemics, the demand for innovative diagnostic solutions is expected to continue driving growth in the global influenza diagnostics market.

Restraints

• High cost limits accessibility
• Regulatory hurdles constrain development
• Limited healthcare infrastructure hampers
• Lack of skilled personnel impedes

• Emerging market challenges persist: Emerging markets continue to grapple with a myriad of challenges, from economic volatility to political instability and infrastructural limitations. These factors significantly impact the healthcare sector, particularly in the realm of diagnostics. The global influenza diagnostics market reflects this complexity, as emerging economies struggle to adopt advanced diagnostic technologies due to cost constraints and inadequate healthcare infrastructure. Additionally, the high variability of influenza strains poses a continuous challenge for diagnostics development and deployment in these regions, further exacerbating the issue.

  Despite these challenges, the global influenza diagnostics market is witnessing steady growth, driven by increasing awareness about the importance of early detection and management of influenza outbreaks. Moreover, advancements in technology, such as the development of rapid diagnostic tests and molecular diagnostics, are gradually making inroads into emerging markets, albeit at a slower pace compared to developed economies. Collaborative efforts between governments, healthcare organizations, and international agencies are crucial in addressing the unique challenges faced by emerging markets in influenza diagnostics, thereby improving healthcare outcomes and mitigating the impact of influenza outbreaks.

Opportunities

• Expanded point-of-care testing
• Innovations in molecular diagnostics
• Collaborations for novel solutions
• Rising demand for rapid tests

• Untapped potential in emerging markets: The global influenza diagnostics market holds significant untapped potential in emerging markets, driven by several factors. Firstly, the rising prevalence of influenza in these regions amplifies the demand for accurate and efficient diagnostic tools. Emerging economies often face challenges in healthcare infrastructure and disease surveillance, making rapid and reliable diagnostic solutions crucial for timely intervention and management. Secondly, advancements in diagnostic technologies, such as molecular diagnostics and point-of-care testing, offer opportunities for market expansion in these regions. These technologies enable faster and more accurate detection of influenza viruses, enhancing healthcare outcomes and reducing the burden on healthcare systems.

  Increasing investments in healthcare infrastructure and the growing awareness about the importance of early disease detection further fuel the growth of the influenza diagnostics market in emerging economies. Governments and healthcare organizations are increasingly focusing on preventive healthcare measures, including the adoption of advanced diagnostic tools, to mitigate the impact of influenza outbreaks. Additionally, strategic collaborations between diagnostic companies and local stakeholders facilitate market penetration and the development of tailored solutions to address the specific needs of emerging markets. Overall, the untapped potential in emerging markets presents lucrative opportunities for stakeholders in the global influenza diagnostics market to expand their presence and contribute to improved healthcare outcomes.

Key players in Global Influenza Diagnostics Market include:

• Abbott Laboratories
• Becton, Dickinson and Company
• Coris BioConcept
• DiaSorin SpA
• F. Hoffmann-La Roche Ltd
• Luminex Corporation
• Meridian Bioscience Inc.
• Quidel Corporation
• Sekisui Diagnostics
• Thermo Fisher Scientific Inc

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis